Pink SheetThe US FDA’s complete response letter for Eli Lilly and Company ’s mirikizumab for ulcerative colitis cements the company’s position as the most frequent big pharma recipient of CRLs for original app
ScripRoyalty financings were relatively few and far between in the first quarter of 2022, but the number of these financings more than doubled in Q1 of 2023 – from three to seven – and the amount of money
ScripThe biopharmaceutical industry showed in multiple ways during the second week of August how a rising tide lifts all ships. Signs that the US may be able to avoid a recession – low unemployment rates a
ScripNeuraxpharm Takes On Established Products From Sanofi Central nervous system specialist Neuraxpharm Arzneimittel GmbH , headquartered in Dusseldorf and Barcelona, announced 12 July that it is strengt